We have initiated a study of cabalactam for mild to moderate Alzheimer’s disease dementia in October. Patients who are formally enrolled will receive 16 weeks of cabalactam treatment with detailed clinical evaluation and laboratory tests. Interested patients may contact Ms. Chen, Research Assistant. Phone 15171470187.